FDA has granted fast-track eligibility to INT230-6 for treatment of patients with triple-negative breast cancer

recently, The U.SFDA(http://has granted fast-track eligibility for programs for patients with recurrent or metastatic triple-negative breast cancer (TNBC) who have previously received at least two treatments for inn230-6 treatments, the company announced, thecompany http://about 15-20% of breast cancerdetected(http://estrogen receptors, progesterone receptors, and HER2 proteins are negative and meet the three-negative criteriaTNBC is considered more aggressive and has a worse prognosis than other types of breast cancer, mainly because the targeting ofdrugs(http://lessAccording to a study published in the Journal of Clinical Oncology, patients who failed two treatments typically progress within nine weeks, and patients who failed to receive three treatments progress within four weeksINT230-6 is the lead candidateproduct (http:// of Intensity Therapeutics, and using its DfuseRxSM technology platform, it was found that the drug is designed for direct injection in tumors, consisting of two proven effective anti-cancer agents and an osmosis-enhancing molecule that helps the drug disperse in the tumor and spread to cancer cells INT230-6 is evaluating Phase I/II clinical studies (NCT0358289) in patients with various advanced solid tumors 　　In preclinical studies, INT230-6 eradicated tumors by directly killing tumors and bringing dendritic cells to the tumor microenvironment to induce antitumor T-cell activation Compared to standard therapies, the use of INT230-6 in vivo models to treat severe cancers can significantly improve overall survival rates In addition, INT230-6 provides long-term, long-lasting protection against multiple revaccinations of the initial cancer and resistance to other cancers in completely realleviated animals in mouse models, INT230-6 has a strong synergy with checkpoint inhibitors, including anti-PD-1 and anti-CTLA4 antibodies The INT230-6 was found on Intensity's dfuserxsm platform